Loading, Please Wait...

CST: 20/06/2018 02:37:30   

Global Central Nervous System Partnering Directory 2012-2018

98 Days ago

Dublin, March 13, 2018 (GLOBE NEWSWIRE) -- The "Global Central Nervous System Partnering 2012-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Global Central Nervous System Partnering 2012 to 2018 provides the full collection of Central Nervous System disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Central Nervous System disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Central Nervous System deals.

The report presents financial deal terms values for Central Nervous System deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Central Nervous System technologies and products.

Report scope

Global Central Nervous System Partnering 2012 to 2018 includes:

  • Trends in Central Nervous System dealmaking in the biopharma industry since 2012
  • Analysis of Central Nervous System deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Central Nervous System deal contract documents
  • Comprehensive access to over 3500 Central Nervous System deal records
  • The leading Central Nervous System deals by value since 2012
  • Most active Central Nervous System dealmakers since 2012

The report includes deals for the following indications: Cerebral palsy, Creutzfeldt Jakob disease, Dizziness, Epilepsy, Faints, Falls, Guillain Barre syndrome, Headache, Meningitis (Bacterial, Meningococcal, Pneumococcal), Mycobacterium tuberculosis (TB), Haemophilus influenzae Type B (Hib), Migraine, Motor Neurone Disease (Amyotrophic Lateral Sclerosis/Lou Gehrig's Disease, Multiple sclerosis, Nausea, Neuropathy, Pain, Neuralgia, Fibromyalgia, Paralysis, Parkinson's disease, Restless leg syndrome, Spinal cord, Stroke, Stuttering, Traumatic Brain Injury, Vertigo, Weakness, plus other CNS indications.

Deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Central Nervous System dealmaking

2.1. Introduction
2.2. Central Nervous System partnering over the years
2.3. Central Nervous System partnering by deal type
2.4. Central Nervous System partnering by industry sector
2.5. Central Nervous System partnering by stage of development
2.6. Central Nervous System partnering by technology type
2.7. Central Nervous System partnering by therapeutic indication

Chapter 3 -Financial deal terms for Central Nervous System partnering

3.1. Introduction
3.2. Disclosed financials terms for Central Nervous System partnering
3.3. Central Nervous System partnering headline values
3.4. Central Nervous System deal upfront payments
3.5. Central Nervous System deal milestone payments
3.6. Central Nervous System royalty rates

Chapter 4 - Leading Central Nervous System deals and dealmakers

4.1. Introduction
4.2. Most active in Central Nervous System partnering
4.3. List of most active dealmakers in Central Nervous System
4.4. Top Central Nervous System deals by value

Chapter 5 - Central Nervous System contract document directory

5.1. Introduction
5.2. Central Nervous System partnering deals where contract document available

Chapter 6 - Central Nervous System dealmaking by therapeutic target

6.1. Introduction
6.2. Deals by Central Nervous System therapeutic target

For more information about this report visit https://www.researchandmarkets.com/research/7wtgzd/global_central?w=12



CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Central Nervous System Drugs